key: cord-0682157-19bhghhw authors: Ge, Shuai; Wang, Xiangjun; Hou, Yajing; Lv, Yuexin; Wang, Cheng; He, Huaizhen title: Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2 date: 2021-01-23 journal: Eur J Pharmacol DOI: 10.1016/j.ejphar.2021.173897 sha: 40b77ea17411b6a6cd7a3e529bf532a6e0876ced doc_id: 682157 cord_uid: 19bhghhw The spread of the corona virus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been intensifying in the past year, posing a huge threat to global health. There is an urgent need for effective drugs and vaccines to fight the COVID-19, but their advent may not be quite fast. Drug repurposing is a feasible strategy in the current situation, which could greatly shorten drug development time and help to response quickly to the novel virus outbreak. It has been reported that histamine H(1) receptor antagonists have broad-spectrum antiviral effects. Therefore, in this study, we aim to screen potential drugs among histamine H(1) receptor antagonists that may inhibit SARS-CoV-2 infection. Based on the model of angiotensin-converting enzyme 2 (ACE2) overexpressing HEK293T cell membrane chromatography (CMC), five FDA-approved histamine H(1) receptor antagonists were found to have bioaffinity to ACE2. Then we determined the interaction between these drugs and ACE2 by frontal analysis and surface plasmon resonance (SPR), which consistently demonstrated that these hits bind to ACE2 at micromolar levels of affinity. Through the pseudovirus assay, we finally identified that doxepin could inhibit SARS-CoV-2 spike pseudovirus from entering the ACE2-expressing cell, reducing the infection rate to 25.82%. These preliminary results indicate that the histamine H(1) receptor antagonist, doxepin, is a viable drug candidate for clinical trials. Therefore, we hope the work timely provides rational help for developing anti-SARS-CoV-2 drugs to control the rapid spread of SARS-CoV-2. was produced. Next, the system should be switch back to the mobile phase A to elute (1) 1 Next, using the K D of doxepin as a reference, the relative standard method was 2 used to calculate the K D of other drugs. The K Dx was determined according to F. (2) . 3 (2) 4 The derivation and interpretation of formulas have been described in previous Cell Counting Kit (7Sea Biotech, Shanghai, China) was used to determine cell 8 viability. 5 × 10 3 of ACE2-HEK293T cells seeded into 96 well plates were incubated 9 for 24 h under standard conditions (37°C and 5% CO 2 ). Then the medium was 10 replaced with serum-free DMEM or DMEM containing histamine H 1 receptor 11 antagonists at concentrations of 25, 50, 100, and 200 μM. The total volume in each 12 well was 100 μl. ACE2-HEK293T cells were incubated in these solutions for 24 h 13 followed by treatment with 10 μl of CCK8 in each well for another 1.5 h at 37°C. The 14 plates were shaken softly before the detection of the optical density at 450 nm (OD 450 ) 15 using a microplate reader (Bio Rad, USA). At least three independent experiments -16 were performed. The survival rate of ACE2-HEK293T cells was calculated using the 17 following formula: 18 Pseudovirus is a chimeric virus particle that expresses a recombinant glycoprotein 2 of another virus on the surface of a replication-defective virus. Pseudovirus 3 neutralization assay can mimic the infectious process of the live virus, which has a 4 good correlation with that measured by the wild type SARS-CoV-2 assay (Xiong et 5 al., 2020) . ACE2-HEK293T cells (5 ×10 4 per well) were seeded into white 96 well -6 plates and cultured at 37°C until cells were adherent. 5 μl of pseudovirus (10 4.4 7 TCID 50 /ml, 860 ng SARS-CoV-2 spike S1 protein/ml) was added to each well, and 8 incubated in a 37°C incubator for 8 hours. After that, the culture medium containing 9 the pseudovirus was aspirated, replaced with 200 μl of new medium, and incubated at 10 37°C for 48 h. Finally, the medium in the 96-well plate were aspirated, 20 μl of cell 11 lysate was added to each well, and shook gently. By adding 100 μl of luminescence 12 solution, luciferase luminescence was detected by FlexStation 3 in a luminescence 13 mode at 560 nm, with exposure time of 1 s. 14 The crystal structure of the SARS-CoV-2 spike receptor-binding domain (S-RBD) 16 bound with ACE2 was obtained from the PDB database (PDB code: 6M0J). To detect the affinity of small molecules with ACE2, SPR analysis was 2 performed through Open SPR TM (Nicoya, waterloo, Canada). Sensor chips coated in 3 nitrilotriacetic acid (NTA) (Nicoya, waterloo Canada) were used for capture ACE2 4 protein containing a poly-histidine tag. 200 μl of 200 mM imidazole and 40 mM 5 NiCl 2 were sequentially injected onto the chip surface to prime the sensor surface and 6 charge the NTA with Ni 2+ . ACE2 was immobilized on NTA chip by loading the 7 ACE2 protein into sensor surface. The pump ran at a flow rate of 20 μl/min. After the 8 baseline was stable, the sample to be analyzed was injected. Experimental data was 9 processed through TraceDrawer and the OneToOne fitting model was used to 10 calculate K D values. 11 Data were analyzed using GraphPad Prism Software 8.0 (GraphPad Software, 13 To discover histamine H 1 receptor antagonists with ACE2 binding activity, cell 1 membrane chromatography was used to randomly screen a series of histamine H 1 2 receptor antagonists. We have screened out five active drugs form dozens of existing 3 histamine H 1 receptor antagonists and the results are shown in Fig. 1 . No significant 4 retention was found in chromatogram of olopatadine, because its retention time is 1. 8 5 min, which is very close to that of the solvent peak. Whereas pyramine, tripinamin, 6 chlorpheniramine, doxylamine, and doxepin have strong retention on the 7 ACE2-HEK293T/CMC column. Their retention time is 20.2, 19.4, 22.9, 11.7, and 8 28.3 min, respectively. 9 The frontier analysis method was used to determine the K D value. In this method, 10 ACE2 on the cell membrane is closer to its actual spatial configuration, making it an 11 effective technique to study the characteristics of drug-membrane receptor affinity. 12 Therefore, the concentration of 20 µM was used as the optimization of these drugs in 8 subsequent experiments because it's non-toxic to ACE2-HEK293T cells. SPR was used to monitor the interactions between molecules and determine the 5 binding specificity between ACE2 and the identified ligand molecules. In this study, 6 the ACE2 protein was immobilized on a carboxyl sensor chip and the identified 7 molecules were passed over the sensor's surface. Then the SPR sensorgrams of the 8 compounds were recorded at the specific concentrations. Chlorpheniramine, doxepin, 9 and doxylamine increased the SPR sensorgrams significantly and in a dose-dependent 10 manner (Fig. 6) . The dissociation constant K D was calculated by fitting the kinetic Due to the urgency of the increasingly serious global pandemic, screening drugs 18 with antiviral potential from existing drugs could shorten the drug development cycle. 19 Studies have shown that histamine H 1 receptor antagonists have the antivirus potential, 20 however whether they play a role in inhibiting SARS-CoV-2 infections is still unclear. 1 Considering that the retention time of the compound on cell membrane 2 chromatography reflects its affinity to membrane receptors (Yuan et al., 2005) , we 3 speculated that the drugs with potent retention in ACE2-HEK293T/CMC column may 4 inhibit SARS-CoV-2 from infecting host cells by binding to ACE2. In this study, we 5 first screened out five antiviral drug candidates from histamine H 1 receptor 6 antagonists used in clinical applications. Olopatadine, without obvious retention 7 behavior, was used as a control. Then a drug concentration that does not affect cell 8 viability for subsequent experiments was determined through cytotoxicity tests. 9 Subsequently, we conducted pseudovirus infection tests with the selected drugs. After 10 were significantly reduced in a dose-dependent manner. Finally, the interaction and 12 the K D of these drugs to ACE2 were investigated through molecular docking and SPR. 13 These results suggested that doxepin has good binding ability to ACE2, indicating 14 that it may inhibit the SARS-CoV-2 from entering host cells by binding to ACE2. We hope our novel discovery will lead to more research to reveal its details. In our study, to further determine the effect of doxepin in inhibiting virus entry into 3 cells, we analyzed its docking conformation with ACE2. Doxepin displays a bonding 4 to the S protein at the molecular level, via hydrophobic interactions and hydrogen 5 bonding. The hydrogen bond can be seen with Lys353, which is a residue that interact 6 with the SARS-CoV-2 S protein RBD directly (Muchtaridi et al., 2020). Thereby 7 doxepin prevented the S protein from contacting ACE2, which may be one of the 8 reasons why it inhibited virus from entering into the cells. Interestingly, although 9 olopatadine also formed hydrogen bonds with an important residue Gln325, its K D to 10 ACE2 was much lower than doxepin. Therefore, no obvious inhibition of virus entry All authors declare that they have no known competing financial interests or 8 personal relationships that could have appeared to influence the work reported in this 9 paper. cells. Experiments were repeated three times, and data are presented as the mean ± 12 S.D. *P < 0.05, **P < 0.01, ***P < 0.001, vs group of no histamine H 1 receptor 13 antagonists. n = 3. 14 A strategic approach to COVID-19 vaccine 4 R&D Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics Screening of bioactive components from 12 traditional Chinese medicines using cell membrane chromatography coupled with mass 13 spectrometry SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically 17 A vascular smooth muscle/cell membrane 19 chromatography-offline-gas chromatography/mass spectrometry method for recognition, 20 separation and identification of active components from traditional Chinese medicines COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at COVID-19 Cell entry mechanisms of 12 SARS-CoV-2 Site-specific glycan analysis 3 of the SARS-CoV-2 spike COVID-19 5 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical 6 pharmacology Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation A noncompeting pair of human neutralizing antibodies block 13 COVID-19 virus binding to its receptor ACE2 Robust neutralization 18 assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus 19 and ACE2-overexpressing BHK21 cells Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity 23 Against a Broad Spectrum of Influenza Viruses